Bal Pharma Limited

Bal Pharma Allots 10 Lakh Warrants to Promoter Shailesh Siroya for ₹8.4 Crore

Bal Pharma Limited approved the allotment of 10,00,000 warrants to Promoter Shailesh Siroya at ₹84 per warrant, totaling ₹8.40 crore. The company received ₹2.10 crore as 25% upfront payment. Warrants are convertible into equity shares within 18 months from the allotment date of September 7, 2026.

Bal Pharma Fixes September 17 as Record Date for ₹1.20 Final Dividend

Bal Pharma Limited has set September 17, 2026, as the record date for its final dividend. Shareholders will receive ₹1.20 per equity share (12% of face value). The dividend payment is scheduled for on or after September 24, 2026. Information on TDS and submission of relevant forms is also provided.

Bal Pharma Announces 39th AGM on Sep 24, 2026; Declares ₹1.20 Dividend

Bal Pharma Limited will hold its 39th AGM on September 24, 2026, via VC/OAVM. The company proposed a dividend of ₹1.20 per equity share for FY 2025-26. Key dates for e-voting and book closure are set for September 2026. The AGM will also address financial statements, director re-appointment, cost auditor remuneration, and related party transactions.

Bal Pharma Announces 39th AGM on Sep 24, 2026; Sets Record Date for Dividend

Bal Pharma Limited will hold its 39th AGM on September 24, 2026, via VC/OAVM. The Record Date for the FY25-26 final dividend is September 17, 2026. E-voting will be open from September 21 to September 23, 2026.

Bal Pharma Clarifies 18-Month Timeline for Preferential Issue Proceeds

Bal Pharma clarifies the 18-month timeline for utilizing net proceeds from its preferential issue, linked to Convertible Warrants. This adheres to SEBI regulations and is subject to stock exchange approval. No changes in issue objectives or fund utilization methods are reported.

Bal Pharma Board Approves Q1 Results, Director Reshuffle, and Philippines JV Investment

Bal Pharma's Board approved Q1 FY27 results, reporting a standalone net profit of ₹1.16 Crore and consolidated net profit of ₹1.14 Crore. The company approved a JV investment of up to ₹9 Crore in the Philippines and a preferential allotment of 10 Lakh Warrants to a promoter for ₹8.40 Crore. Director designations were changed, effective October 1, 2026.

Bal Pharma Board Approves FY27 Q1 Results, Director Re-designations, and Philippines JV Investment

Bal Pharma approved Q1 FY27 results, noting revenue from operations of ₹88.43 crore (standalone) and ₹89.05 crore (consolidated). The board approved Mr. Kothari's re-designation to Executive Director and Mr. Himesh's to Non-Executive Director from Oct 1, 2026. An investment of up to ₹9 crore in a Philippines JV was approved, alongside the allotment of 10 lakh warrants to promoter Shailesh Siroya for ₹8.40 crore.

Bal Pharma shareholders approve 10 Lakh Warrants to Promoter via Postal Ballot

Bal Pharma shareholders approved the issuance of 10,00,000 Warrants to the Promoter on a preferential basis. The postal ballot results, declared on August 10, 2026, showed 99.96% of votes in favor. The remote e-voting period was from July 10, 2026, to August 08, 2026.

Bal Pharma Extends Comment Period for Postal Ballot Following Corrigendum

Bal Pharma is extending the comment period for its postal ballot by 48 hours following a corrigendum. Shareholders who voted prior to the corrigendum can revise their votes. The remote e-voting facility remains open until August 8, 2026.

Bal Pharma clarifies financial results, refiles XBRL; approves dividend, stock options

Bal Pharma refiled XBRL financial results due to technical variations, confirming PDF figures are final. The Board approved FY26 audited results, recommended a 12% dividend (Re.1.20/share), granted 500,000 stock options, and approved a preferential issue of warrants to promoters. Mr. Shreepada ML appointed as Company Secretary.

Bal Pharma revises preferential issue price to ₹84/warrant, total ₹8.4 crore

Bal Pharma revises preferential issue price to ₹84 per warrant, raising ₹8.4 crore for a Greenfield API manufacturing facility. Payment terms adjusted to 25% on allotment and 75% before conversion. E-voting period remains July 10 to August 8, 2026. Shareholding pattern updated on a fully diluted basis.

Bal Pharma Confirms SEBI DP Reg. Compliance for Q1 FY27

Bal Pharma Limited confirms compliance with SEBI DP Regulations for the quarter ended June 30, 2026. Details of dematerialized/rematerialized securities were submitted to stock exchanges on time. Share certificates received for dematerialization were processed within 15 days.

Bal Pharma Limited Closes Trading Window from July 1, 2026, for Q1 FY27 Results

Bal Pharma Limited will close its trading window from July 1, 2026, until 48 hours after the declaration of Q1 FY27 unaudited financial results for the quarter ended June 30, 2026. The company will announce the Board meeting date for results declaration separately.

Bal Pharma Announces Audited Financial Results for FY26; Declares Dividend

Bal Pharma Limited announced audited standalone and consolidated financial results for the quarter and FY ended March 31, 2026. The Board approved the results on May 27, 2026, and declared a final dividend of ₹2.5 per share. The results were published on May 29, 2026.

Bal Pharma Limited: Statement of Deviation/Variation Not Applicable for Q4FY26

Bal Pharma Limited states that the statement of deviation/variation in fund utilization is not applicable for the quarter ended March 31, 2026. The company has not raised funds via public issue, rights issue, preferential issue, or QIP, and has no outstanding funds from earlier issues requiring utilization.

Bal Pharma Board Approves FY26 Results, Recommends Dividend, Approves Warrants & ESOPs

Bal Pharma's Board approved FY26 results and recommended a dividend of ₹1.20 per share. The company will issue 10,00,000 warrants to promoters and grant 5,00,000 stock options to employees. Mr. Shreepada ML appointed as Company Secretary.

Bal Pharma Board Approves FY26 Results, Recommends Dividend, Approves Preferential Issue

Bal Pharma board approved FY26 audited results and recommended a dividend of Re.1.20/share. The company will issue 10,00,000 warrants to promoters via preferential issue and approved 5,00,000 stock options for employees. Mr. Shreepada ML was appointed Company Secretary.

Bal Pharma Board Approves FY26 Results, Recommends Dividend, and Plans Warrants Issue

Bal Pharma approved FY26 audited financial results and recommended a dividend of ₹1.20 per share. The company will issue 10 lakh warrants to promoters and 5 lakh stock options to employees. Mr. Shreepada ML was appointed Company Secretary.

Bal Pharma to Consider Preferential Issue of Warrants to Promoters on May 27

Bal Pharma Limited's Board Meeting on May 27, 2026, will now include consideration of a preferential issue of warrants to promoters for fundraising. This is an addendum to a previously announced meeting.

Bal Pharma Limited Files Compliance Certificate for Q4 FY26

Bal Pharma Limited filed a compliance certificate for the quarter ended March 31, 2026, confirming its Structured Digital Database (SDD) meets SEBI (PIT) Regulations. The database captures UPSI with an audit trail and is maintained internally.

Bal Pharma Ltd Confirms SEBI Compliance for Quarter Ended March 31, 2026

Bal Pharma Limited confirmed compliance with SEBI regulations for the quarter ending March 31, 2026. Details of securities dematerialized/rematerialized were furnished to stock exchanges within the prescribed time limit, based on R&T agent certificates.

Bal Pharma Limited Closes Trading Window from April 18 for FY26 Financial Results

Bal Pharma Limited will close its trading window from April 18, 2026. This is in accordance with SEBI regulations and will remain closed until 48 hours after the announcement of audited financial results for the quarter and financial year ending March 31, 2026.

Bal Pharma Ltd. Publishes Unaudited Financial Results for Q3 FY26

Bal Pharma Limited published its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025. The results were announced on February 1, 2026, and published in Financial Express and Sanjevani on February 13, 2026, as per SEBI regulations.

Bal Pharma Q3FY26 Unaudited Results: Net Profit ₹194.62 Lakhs Standalone, ₹177.99 Lakhs Consolidated

Bal Pharma reported unaudited standalone net profit of ₹194.62 Lakhs and consolidated net profit of ₹177.99 Lakhs for Q3FY26. Revenue from operations was ₹8,749.48 Lakhs (standalone) and ₹8,768.97 Lakhs (consolidated). Auditors issued an unmodified opinion.

Bal Pharma shareholders approve Dr. Mukesh Beekamchand as Independent Director

Bal Pharma shareholders approved the appointment of Dr. Mukesh Beekamchand as a Non-Executive Independent Director for five years. The resolution passed with 99.98% of votes in favour. The appointment is effective until February 6, 2031. This follows a postal ballot process.

Bal Pharma Limited: Newspaper Publication of Postal Ballot Notice

Bal Pharma Limited published a postal ballot notice for the appointment of Mr. Mukesh Beekamchand as Non-Executive Independent Director for a 5-year term. E-voting is open from January 12, 2026, to February 7, 2026. The notice was published in Financial Express and Sanjevani.

Bal Pharma Confirms SEBI Compliance on Dematerialization for Q3FY26

Bal Pharma Limited confirms compliance with SEBI regulations for the quarter ended December 31, 2025. Details of dematerialized securities were submitted to stock exchanges within the prescribed time limit, based on certificates from their R&T agent.

Bal Pharma Seeks Shareholder Approval for Dr. Mukesh Beekamchand's Independent Director Appointment

Bal Pharma is seeking shareholder approval via postal ballot for the appointment of Dr. Mukesh Beekamchand as an Independent Director. Remote e-voting is open from January 9 to February 7, 2026. Dr. Beekamchand has over 25 years of experience and meets independence criteria. Results are expected by February 10, 2026.

Bal Pharma: Trading Window Closed from Jan 18 for Q3 FY26 Results

Bal Pharma Limited will close its trading window from January 18, 2026. This closure is in anticipation of the declaration of unaudited financial results for the quarter ended December 31, 2025, and will last for 48 hours post-announcement.

Bal Pharma reports Q2 FY26 standalone and consolidated net loss of 6.41 lakhs

Bal Pharma published Q2 FY26 unaudited standalone and consolidated financial results, reporting a net loss of 6.41 lakhs for the quarter ended September 30, 2025, with EPS at (0.09).

Bal Pharma reports decline in Q2 and H1 FY26 profits; Appoints Dr. Bheekamchand Mukesh as Director

Bal Pharma Limited announced a decline in standalone and consolidated net profits for Q2 and H1 FY26, alongside the appointment of Dr. Bheekamchand Mukesh as an additional independent director.

Bal Pharma Approves Unaudited Financial Results for Quarter Ended Sep 30, 2025

Bal Pharma approved unaudited financial results for quarter ended Sep 30, 2025, appointed Dr. Bheekamchand Mukesh as an additional director. Standalone revenue from operations for the quarter ended September 30, 2025, was ₹7,374.95 lakh.

Clarification on Deferred Merger Proposal of Lifezen Healthcare

Bal Pharma clarified that the board meeting on August 11, 2025, deferred the merger of Lifezen Healthcare due to insufficient data, instructing management to re-present the proposal.

Compliance certificate for Structured Digital Database for quarter ended 30 Sep 2025

Bal Pharma Limited confirms the existence of a Structured Digital Database (SDD) for the quarter ended September 30, 2025, ensuring compliance with SEBI regulations.

Confirmation of Dematerialization as per SEBI Regulations

Bal Pharma confirms compliance with SEBI regulations for dematerialization/rematerialization of securities for the quarter ended September 30, 2025, ensuring timely submission to stock exchanges.

Mr. H.S Venkatesh Completes Tenure as Independent Director at Bal Pharma

Bal Pharma's 38th AGM adopts FY25 financials, declares ₹1.20 dividend, approves ESOP

Bal Pharma sets 18 September 2025 as record date for FY25 dividend, pending AGM approval

Bal Pharma Approves Unaudited Financial Results for Quarter Ended June 30, 2025